AbbVie acquired Gilgamesh's pipeline drug while FDA leadership shifts weighed on deal-making among major pharmaceutical companies.
5 reports, 4 independent
Updated Aug 27
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 5
- Developments
- 1
- Repetition
- 80%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie acquired Gilgamesh's pipeline drug while FDA leadership shifts weighed on deal-making among major pharmaceutical companies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AbbVie
pharmaceutical company
- FDA
-
Gilgamesh Pharmaceuticals
American pharmaceutical company
Nothing else this week.
Related events
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- Fed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.
- Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
Coverage
Newest first; wire copies grouped- ZacksWhat Is the Intent Behind AbbVie's Recent Acquisition Spree? AbbVie ABBV has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline, which should drive long-term
- Pharma VoiceAbbVie dives back into the neuro pool with a $1.2B psychedelics play This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice ne
- ZacksABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeli
- Pharmaceutical TechnologyAbbVie agrees to acquire Gilgamesh’s bretisilocin for $1.2bn AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.
- BioPharma DiveAbbVie to pay $700M for trispecific drug from Ichnos Glenmark This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive new